Psychiatric Drug Treatment and Drug Addiction

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 23 July 2024 | Viewed by 835

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmacology, Faculty of Medicine, University of Murcia, 30100 Murcia, Spain
Interests: neurobiological mechanisms; drug addiction; neuropharmacology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), drug addiction is a psychiatric disorder presenting a major public health burden across the world, especially in developed countries. People with drug dependence usually have more psychiatric conditions or are prescribed psychiatric drugs. Nowadays, new treatments for patients to prevent relapses, one of the main problems of drug addiction, are imperative. Also, drugs that improve the quality of life of these patients are necessary. Furthermore, we are currently living in a time with the most people diagnosed with mental issues in history. For these reasons, we are particularly interested in insights into new psychiatric drugs and new treatments for drug addiction for this Special Issue. Research articles and reviews investigating drugs of abuse and psychiatric drugs, commercialized or not (as well as drugs in the clinical trial phase), are also welcome.

Dr. Javier Navarro-Zaragoza
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug addiction
  • drug abuse
  • psychiatric disorder
  • drug dependence

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1333 KiB  
Article
Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study
by Stefania Chiappini, Clara Cavallotto, Alessio Mosca, Francesco Di Carlo, Tommaso Piro, Giulia Giovannetti, Arianna Pasino, Mariachiara Vicinelli, Chiara Lorenzini, Mariapia Di Paolo, Maria Pepe, Marco Di Nicola, Valerio Ricci, Mauro Pettorruso and Giovanni Martinotti
Pharmaceuticals 2024, 17(4), 535; https://doi.org/10.3390/ph17040535 - 21 Apr 2024
Viewed by 669
Abstract
Background: Dual disorders (DDs) involve the coexistence of a substance use disorder (SUD) with another mental illness, often from the psychotic and affective categories. They are quite common in clinical practice and present significant challenges for both diagnosis and treatment. This study explores [...] Read more.
Background: Dual disorders (DDs) involve the coexistence of a substance use disorder (SUD) with another mental illness, often from the psychotic and affective categories. They are quite common in clinical practice and present significant challenges for both diagnosis and treatment. This study explores the effectiveness of brexpiprazole, a third-generation antipsychotic, in an Italian sample of individuals diagnosed with schizophrenia spectrum disorder and a comorbid SUD. Methods: Twenty-four patients, diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and enrolled in several Italian hospitals, underwent a psychometric assessment at baseline (T0) and one month (T1) after starting brexpiprazole treatment administered at a mean dosage of 2 mg/day. Results: Brexpiprazole demonstrated significant reductions in psychopathological burden (Positive and Negative Syndrome Scale/PANSS total score: p < 0.001). Positive (p = 0.003) and negative (p = 0.028) symptoms, substance cravings (VAS craving: p = 0.039), and aggression (MOAS scale: p = 0.003) were notably reduced. Quality of life improved according to the 36-item Short Form Health Survey (SF-36) subscales (p < 0.005). Conclusions: This study provides initial evidence supporting brexpiprazole’s efficacy and safety in this complex patient population, with positive effects not only on psychopathology and quality of life, but also on cravings. Further studies involving larger cohorts of subjects and extended follow-up periods are needed. Full article
(This article belongs to the Special Issue Psychiatric Drug Treatment and Drug Addiction)
Show Figures

Figure 1

Back to TopTop